AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process

Following negotiations, AstraZeneca’s clot buster Brilique has been awarded a price that has pleased both the manufacturer and health insurers – but industry as a whole remains skeptical of the system.